Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.

PloS one - 1 Jan 2013

Malm Magdalena, Kronqvist Nina, Lindberg Hanna, Gudmundsdotter Lindvi, Bass Tarek, Frejd Fredrik Y, Höidén-Guthenberg Ingmarie, Varasteh Zohreh, Orlova Anna, Tolmachev Vladimir, Ståhl Stefan, Löfblom John

Abstract excerpt

The HER3 receptor is implicated in the progression of various cancers as well as in resistance to several currently used drugs, and is hence a potential target for development of new therapies. We have previously generated Affibody molecules that inhibit heregulin-induced signaling of the HER3 pathways. The aim of this study was to improve the affinity of the binders to hopefully increase receptor inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to Biosensing Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Circular Dichroism

Share to Inhibitory Concentration 50

Share to Ligands

Share to Peptide Library

Share to Receptor, ErbB-3

Share to Recombinant Fusion Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 23675426
DOI: 10.1371/journal.pone.0062791
PMCID: PMC3651084

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.PMID 23675426Read ↗

Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody moleculesSemantic proximity Read ↗

Affinity maturation of antibodies assisted by in silico modeling.Semantic proximity Read ↗

Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling.Semantic proximity Read ↗

Directed Evolution of PD-L1-Targeted Affibodies by mRNA DisplaySemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

A high throughput bispecific antibody discovery pipelineSemantic proximity Read ↗

A high throughput bispecific antibody discovery pipelineSemantic proximity Read ↗

Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCRSemantic proximity Read ↗

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody propertiesSemantic proximity Read ↗

Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.Semantic proximity Read ↗

Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodiesSemantic proximity Read ↗

Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.